



# A Comparison of MRI Quantitative Susceptibility Mapping and TRUST-Based Measures of Brain Venous Oxygen Saturation in Sickle Cell Anaemia

Russell Murdoch<sup>1†</sup>, Hanne Stotesbury<sup>2†</sup>, Patrick W. Hales<sup>2</sup>, Jamie M. Kawadler<sup>2</sup>, Melanie Kölbl<sup>2</sup>, Christopher A. Clark<sup>2</sup>, Fenella J. Kirkham<sup>2,3</sup> and Karin Shmueli<sup>1\*</sup>

<sup>1</sup>Department of Medical Physics and Biomedical Engineering, University College London, London, United Kingdom,

<sup>2</sup>Developmental Neurosciences, UCL Great Ormond Street Institute of Child Health, London, United Kingdom, <sup>3</sup>Clinical and Experimental Sciences, University of Southampton, Southampton, United Kingdom

## OPEN ACCESS

### Edited by:

Ozlem Yalcin,  
Koç University, Turkey

### Reviewed by:

Banu Oflaz Sözmen,  
Koç University, Turkey  
Umut A. Gurkan,  
Case Western Reserve University,  
United States

### \*Correspondence:

Karin Shmueli  
k.shmueli@ucl.ac.uk

<sup>†</sup>These authors have contributed  
equally to this work and share first  
authorship

### Specialty section:

This article was submitted to  
Red Blood Cell Physiology,  
a section of the journal  
Frontiers in Physiology

Received: 05 April 2022

Accepted: 15 June 2022

Published: 29 August 2022

### Citation:

Murdoch R, Stotesbury H, Hales PW,  
Kawadler JM, Kölbl M, Clark CA,  
Kirkham FJ and Shmueli K (2022) A  
Comparison of MRI Quantitative  
Susceptibility Mapping and TRUST-  
Based Measures of Brain Venous  
Oxygen Saturation in Sickle  
Cell Anaemia.  
Front. Physiol. 13:913443.  
doi: 10.3389/fphys.2022.913443

In recent years, interest has grown in the potential for magnetic resonance imaging (MRI) measures of venous oxygen saturation ( $Y_v$ ) to improve neurological risk prediction.  $T_2$ -relaxation-under-spin-tagging (TRUST) is an MRI technique which has revealed changes in  $Y_v$  in patients with sickle cell anemia (SCA). However, prior studies comparing  $Y_v$  in patients with SCA relative to healthy controls have reported opposing results depending on whether the calibration model, developed to convert blood  $T_2$  to  $Y_v$ , is based on healthy human hemoglobin (HbA), bovine hemoglobin (HbBV) or sickle hemoglobin (HbS). MRI Quantitative Susceptibility Mapping (QSM) is an alternative technique that may hold promise for estimating  $Y_v$  in SCA as blood magnetic susceptibility is linearly dependent upon  $Y_v$ , and no significant difference has been found between the magnetic susceptibility of HbA and HbS. Therefore, the aim of this study was to compare estimates of  $Y_v$  using QSM and TRUST with five published calibration models in healthy controls and patients with SCA. 17 patients with SCA and 13 healthy controls underwent MRI. Susceptibility maps were calculated from a multi-parametric mapping acquisition and  $Y_v$  was calculated from the mean susceptibility in a region of interest in the superior sagittal sinus. TRUST estimates of  $T_2$ , within a similar but much smaller region, were converted to  $Y_v$  using five different calibration models. Correlation and Bland-Altman analyses were performed to compare estimates of  $Y_v$  between TRUST and QSM methods. For each method, t-tests were also used to explore group-wise differences between patients with SCA and healthy controls. In healthy controls, significant correlations were observed between QSM and TRUST measures of  $Y_v$ , while in SCA, there were no such correlations. The magnitude and direction of group-wise differences in  $Y_v$  varied with method. The TRUST-HbBV and QSM methods suggested decreased  $Y_v$  in SCA relative to healthy controls, while the TRUST-HbS ( $p < 0.01$ ) and TRUST-HbA models suggested increased  $Y_v$  in SCA as in previous studies. Further validation of all MRI measures of  $Y_v$ , relative to ground truth measures such as  $O^{15}$  PET and jugular vein catheterization, is required in SCA before QSM or TRUST methods can be considered for neurological risk prediction.

**Keywords:** sickle cell anaemia, T2-relaxation-under-spin-tagging, quantitative susceptibility mapping, venous oxygen saturation, validation, magnetic resonance imaging

## 1 INTRODUCTION

Sickle cell anemia (SCA) is an inherited blood disorder characterized by hemolytic anemia, vasculopathy, cognitive difficulties and high incidence of ischemic stroke, and silent cerebral infarction (Debaun and Kirkham 2016; Stotesbury et al., 2019). The mechanism for these complications in SCA are poorly understood and current methods of risk prediction in SCA are non-specific and have not been validated in adults (Stotesbury et al., 2018; Stotesbury et al., 2021).

Interest has grown in the potential for magnetic resonance imaging (MRI) estimates of venous oxygen saturation ( $Y_v$ ), and the closely related oxygen extraction fraction (OEF), to improve neurological risk prediction in SCA (Jordan and DeBaun 2018). Measuring  $Y_v$  *in-vivo* is challenging, and all oxygen-sensitive MRI techniques rely on models to convert the MRI measures into  $Y_v$ . Questions remain around the validity of these models, particularly in conditions such as SCA where alterations in blood rheology and oxygen-carrying capacity may challenge model assumptions.

In this study we aimed to compare measures of  $Y_v$  in SCA, and healthy controls (HC) subjects, derived from two MRI methods:  $T_2$ -relaxation-under-spin-tagging (TRUST) and the more recently developed quantitative susceptibility mapping (QSM).

TRUST is based on the principle that the transverse relaxation time of blood ( $T_{2b}$ ) is dependent on its oxygen saturation (Lu et al., 2012) and has been widely used to estimate  $Y_v$ . TRUST

applies similar principles to arterial spin labelling (ASL) to isolate the signal from venous blood, and uses  $T_2$  preparation pulses to acquire signal at a series of effective echo times (eTE). The venous blood  $T_2$  is then estimated from an exponential fit of the signal from venous blood ( $\Delta S$ ) as a function of eTE:

$$\Delta S = \Delta S_0 \cdot e^{-\frac{eTE}{T_{1b} - T_{2b}}} \quad (1)$$

Where  $\Delta S_0$  is the signal intensity difference at eTE = 0 and  $T_{1b}$  is the longitudinal relaxation time of venous blood.

Five calibration models have been previously developed to convert the venous blood  $T_2$  measured using TRUST to  $Y_v$ : one based on bovine-hemoglobin (HbBV) (Lu et al., 2012; Jordan et al., 2016), one on hemoglobin-A (HbA) (Bush et al., 2017), and three derived from hemoglobin-S: HbS<sub>Bush</sub> (Bush et al., 2018), HbS<sub>Li</sub> (Li et al., 2020) and HbS<sub>Li-Bush</sub> (Bush et al., 2021). These models are described in detail in the **Supplementary materials**. Using TRUST,  $Y_v$  can appear either increased or decreased in SCA relative to healthy controls depending on the calibration model used (Lin et al., 2022). An overview of published studies applying TRUST in SCA subjects is shown in **Table 1**.

QSM is a more recent MRI technique that reconstructs the spatial distribution of magnetic susceptibility ( $\chi$ ) from gradient-echo (GRE) phase images (Shmueli 2020). QSM measures of  $Y_v$  are based on the observation that hemoglobin in its oxygenated form is weakly diamagnetic, while deoxygenated hemoglobin is

**TABLE 1** | Overview of the previous literature investigating the effect of sickle cell anemia (SCA) on venous oxygen saturation ( $Y_v$ ) and oxygen extraction fraction (OEF) relative to healthy controls (HC). Abbreviations:  $T_2$ -relaxation-under-spin-tagging (TRUST), asymmetric spin echo (ASE), positron emission tomography (PET).

### MRI TRUST Studies

| Author               | Year | Calibration model      | Number of SCA subjects (age mean $\pm$ S.D., years) | Number of healthy control (HC) subjects (age mean $\pm$ S.D., years) | Results   |
|----------------------|------|------------------------|---|--|---|
| Jordan et al. (2016) | 2016 | HbBV                   | 27 (27.7 $\pm$ 5.0)                                 | 11 (26.9 $\pm$ 5.1)  | $Y_v$ decreased in SCA vs. HC (52.0 $\pm$ 7.5% vs. 63.2 $\pm$ 6.1%, $p < 0.05$ )                |
| Bush et al. (2018)   | 2017 | HbS <sub>Bush</sub>    | 33 (21.8 $\pm$ 9.0)                                 | 37 (27.2 $\pm$ 10.6)   | $Y_v$ increased in SCA vs. HC (73 $\pm$ 5% vs. 61 $\pm$ 6%, $p < 0.0001$ )                      |
| Li et al. (2020)     | 2019 | Subject Specific       | 11 (25 $\pm$ 7)                                     | 12 (35 $\pm$ 7)  | No significant OEF differences between SCA and HC (37.5 $\pm$ 5% vs. 38.9 $\pm$ 5% $p = 0.31$ ) |
| Vu et al. (2021)     | 2021 | HbS <sub>Li-Bush</sub> | 47 (21.7 $\pm$ 7.1)                                 | 44 (26.4 $\pm$ 10.6)   | OEF significantly decreased in SCA vs. HC (27.4 $\pm$ 4.1% vs. 36.7 $\pm$ 6.0%, $p < 0.01$ )    |

### MRI QSM Studies

| Author                | Year | ROI                     | Number of SCA subjects | Number of Healthy Control (HC) subjects | Results  |
|-----------------------|------|-------------------------|------------------------|---|--|
| Shen et al. (2019)    | 2019 | Straight Sinus          | 16 (24 $\pm$ 7)        | 11 (25 $\pm$ 9)                         | $Y_v$ decreased in SCA vs. HC (69.3% vs. 73.9%, $p < 0.05$ ) |
| Murdoch et al. (2021) | 2021 | Superior Sagittal Sinus | 88 (18.4 $\pm$ 10.0)   | 30 (18.0 $\pm$ 9.6)                     | $Y_v$ decreased in SCA vs. HC (72.3 vs. 74.5, $p < 0.005$ )  |

### MRI and PET Whole Brain Studies

| Author               | Year | Method       | Number of SCA subjects | Number of Healthy Control (HC) subjects | Results   |
|----------------------|------|--------------|------------------------|---|---|
| Fields et al. (2018) | 2017 | ASE          | 36 (10.0)              | 20 (11.0)                               | Whole-brain OEF increased in SCA (42.7 vs. 28.8 $p < 0.001$ ) |
| Herold et al. (1986) | 1986 | $O^{15}$ PET | 6 (27.5 $\pm$ 8.7)     | 14 (34.3 $\pm$ 7.0)                     | No significant OEF differences (42 $\pm$ 4% vs. 44 $\pm$ 7%)  |

strongly paramagnetic. Therefore, the measured  $\chi$  of venous blood relative to the surrounding tissue ( $\Delta\chi_{\text{vein-water}}$ , assuming that surrounding tissue has the same  $\chi$  as water), should be directly proportional to the concentration of deoxygenated hemoglobin (Jain et al., 2012).  $\Delta\chi_{\text{vein-water}}$  and  $Y_v$  are linearly related by the following expression (Weisskoff and Kühne 1992):

$$Y_v = 1 - \frac{\Delta\chi_{\text{vein-water}} - \Delta\chi_{\text{oxy-water}} \cdot \text{Hct}}{\Delta\chi_{\text{do}} \cdot \text{Hct}} \quad (2)$$

Where hematocrit (Hct) is the percentage of erythrocytes in blood,  $\Delta\chi_{\text{do}}$  is the  $\chi$  shift between fully oxygenated and deoxygenated erythrocytes [ $0.27 \times 4\pi$  ppm (SI)] and  $\Delta\chi_{\text{oxy-water}}$  is the  $\chi$  shift between oxygenated erythrocytes and water [ $-0.03 \times 4\pi$  ppm (SI)] (Weisskoff and Kühne 1992).

QSM has been shown to be sensitive to changes in  $Y_v$ /OEF in conditions which affect cerebral oxygen metabolism and/or blood flow. Oxygen extraction fraction is defined as the arteriovenous difference in oxygen saturation, and increased OEF corresponds to decreased  $Y_v$ , for a given arterial oxygen saturation. QSM was sensitive to changes in hemispheric venous oxygen saturation in patients with acute stroke: increased QSM-based OEF was observed in cerebral veins in the affected hemisphere relative to the contralateral hemisphere ( $29.3 \pm 3.4\%$  versus  $25.5 \pm 3.1\%$   $p < 0.032$ ) (Fan et al., 2020). QSM has also been applied in patients with arteriovenous malformations (AVMs), showing that veins draining AVMs had significantly higher  $Y_v$  compared to healthy veins as a result of arteriovenous shunting (Biondetti et al., 2019).

Previous work in a pilot study of 6 SCA patients and 6 healthy controls has demonstrated no significant  $\chi$  difference between deoxyhemoglobin in sickle and normal erythrocytes, suggesting that QSM is valid in both SCA and healthy controls (HC) (Eldeniz et al., 2021). To date, only two studies of  $Y_v$  in SCA have been carried out using QSM, with both studies reporting decreased  $Y_v$  in SCA relative to HC (Shen et al., 2019; Murdoch et al., 2021).

TRUST is a global measure of  $Y_v$ , derived from  $T_2$  values fitted within a small region of interest (ROI) in the superior sagittal sinus (SSS) within a single slice. QSM can also be used to derive a similar global measure of  $Y_v$  by estimating the mean magnetic susceptibility within a ROI in the SSS. In QSM, the ROI can be a three-dimensional volume spanning several slices and including many more voxels than the region used in TRUST.

Aiming to improve our understanding of  $Y_v$  estimation in SCA, we compared measures of global  $Y_v$  derived from QSM and TRUST using each of the five calibration models.

## 2 MATERIALS AND METHODS

### 2.1 Patients

Patients with sickle cell anemia (SCA; hemoglobin-SS) and age matched healthy controls were recruited to two concurrent studies with overlapping MRI protocols between 2016 and 2019: the Sleep Asthma Cohort follow-up (SAC) (Rosen et al., 2014) and the Prevention of Morbidity in Sickle Cell Anemia

baseline investigation (POMS) (Howard et al., 2018). Inclusion and exclusion criteria have been described elsewhere (Stotesbury et al., 2022). In 2018, the TRUST sequence was added to both MRI protocols as an optional sequence for participants who tolerated the core protocol. Participants from both studies with TRUST data were eligible for inclusion.

Fetal hemoglobin (HbF) concentration, absolute reticulocyte count (ARC) and lactate dehydrogenase (LDH) were not collected as part of this study. Steady state HbF concentration, ARC and LDH were available in participants recruited from the UK National Health Service (NHS) who consented for collection of this information for research purposes and not available in the patients recruited from the community (Table 2).

Ethical approval was granted by West London NHS (05/Q0408/42, 11/EM/0084, 15/LO/0347), Yorkshire NHS (15/YH/0213), and University College London (14475/001) ethics committees. Full informed consent and assent according to the Declaration of Helsinki were obtained from participants and, for children, from their parent/guardian.

### 2.2 MRI Acquisition

All participants were imaged on a 3T Siemens (Erlangen, Germany) Magnetom Prisma MRI System using a 64-channel head coil. The MRI protocol included a TRUST sequence with repetition time (TR) = 3000 ms, inversion time (TI) = 1020 ms, voxel size =  $3.44 \times 3.44 \times 5$  mm<sup>3</sup>, matrix size =  $64 \times 64 \times 1$ , effective echo time (eTE) = 0, 40, 80, 160 ms, label slab = 100 mm and 3 averages. This was followed by a multi-parametric mapping (MPM) acquisition comprised of three fast low angle shot (FLASH) GRE sequences with respective magnetization transfer (MT), proton density (PD) and  $T_1$  weighting. The PD-weighted sequence parameters were: TR = 24.5 ms, TE<sub>1</sub> = 2.34 ms,  $\Delta$ TE = 2.34 ms, echoes = 8, flip angle = 6°, voxel size = 1 mm<sup>3</sup> isotropic.  $T_1$ -weighting was introduced by increasing the flip angle to 20° with all other parameters kept the same. MT-weighting was introduced by applying off-resonance saturation pulses prior to excitation with the number of echoes reduced to 6 to maintain consistent TR.

During the MRI examination, peripheral oxygen saturation (SpO<sub>2</sub>) was measured using a pulse oximeter. Blood T1 was estimated from blood hematocrit and measured SpO<sub>2</sub> (Hales et al., 2016). In one SCA subject, pulse oximetry measures of SpO<sub>2</sub> were not available and the mean SpO<sub>2</sub> across SCA patients (97.47%) was used.


### 2.3 MRI Processing

#### 2.3.1 TRUST Processing

For each eTE, difference images were calculated between the TRUST label and control images. An initial square ROI was manually drawn covering the superior sagittal sinus (SSS). The SSS ROI was defined by selecting the four voxels with the largest signal intensity in the difference image with the shortest eTE (eTE = 0 ms). Signal intensities in the difference images were averaged over all four voxels for each eTE and estimates of the venous  $T_2$  ( $T_{2b}$ ) were estimated from a fit of these intensities as a function of eTE (Eq. 1).

**TABLE 2** | Overview of the sickle cell anemia (SCA) and healthy control (HC) subjects included in this study.

|  | SCA             | HC             |
|--|-----------------|----------------|
| N  | 17              | 13             |
| Age (Mean $\pm$ SD) (years)  | 20.1 $\pm$ 4.7  | 21.2 $\pm$ 3.9 |
| Male/Female  | 9/8             | 4/9            |
| SpO <sub>2</sub> (measured/estimated)  | 16/1            | 13/0           |
| SpO <sub>2</sub> (Mean $\pm$ SD) (%)   | 97.5 $\pm$ 2.4  | 99.4 $\pm$ 0.8 |
| Hematocrit (measured/estimated)  | 12/5            | 0/13           |
| Hematocrit (Mean $\pm$ SD) (%)   | 26.3 $\pm$ 4.1  | 41.4 $\pm$ 3.3 |
| Hemoglobin (Mean $\pm$ SD) (g/dl)  | 9.02 $\pm$ 1.47 | NA             |
| Hydroxyurea Treatment (Yes)  | 6 (35%)         | NA             |
| Transfusion Last 6 Months (Yes)  | 7 (41%)         | NA             |
| Chronic Transfusions (Yes)   | 3 (18%)         | NA             |
| Silent Cerebral Infarcts (Yes)   | 8 (47%)         | 2 (15%)        |
| Previous Acute Chest Crisis (Yes) ( <i>n</i> = 15)                                 | 9/15 (60%)      | NA             |
| Fetal Hemoglobin (Mean $\pm$ SD) (%) ( <i>n</i> = 13)                              | 8.75 $\pm$ 7.36 | NA             |
| Absolute Reticulocyte Count (ARC) (Mean $\pm$ SD) (cells/ $\mu$ l) ( <i>n</i> = 8) | 287 $\pm$ 105   | NA             |
| Lactate dehydrogenase (LDH) (Mean $\pm$ SD) (IU/L) ( <i>n</i> = 15)                | 679 $\pm$ 354   | NA             |



Venous oxygen saturation ( $Y_v$ ) was estimated from  $T_{2b}$  using previously derived calibration models based on bovine (HbBV) and healthy (HbA) hemoglobin, as well as three models based on sickle hemoglobin; the Bush (HbS<sub>Bush</sub>), Li (HbS<sub>Li</sub>) and combined Li-Bush (HbS<sub>Li-Bush</sub>) models. Full details on each model are provided in the **Supplementary materials**.


For the 12 SCA subjects with blood samples taken, measures of hematocrit from the blood drawn closest to the MRI examination were selected. In the remaining 5 SCA subjects, hematocrit was estimated as the mean hematocrit of this cohort (26.3%).

Study ethics did not cover taking blood samples from healthy control subjects and hematocrit had to be estimated. Not all controls in this study were race-matched to the SCA participants and hematocrit estimates in white and black controls were derived from two different sources. In the white control


subjects (all aged 20–30) hematocrit was estimated as 0.47 in males and 0.42 in females (Kratz et al., 2004). In the black control subjects hematocrit was estimated from a study which investigated the effect of age and sex upon blood hematocrit values in healthy black Americans (Castro et al., 1987); estimated hematocrit values ranged from 0.35 to 0.42 depending upon patient demographic.

### 2.3.2 QSM Processing

Maps of magnetic susceptibility ( $\chi$ ) were calculated from each of the three MPM FLASH acquisitions in their own native space via the following pipeline: total field maps were estimated from a non-linear fit of the complex multi-echo images (Liu et al., 2013), residual wraps in the field map were removed using SEGUE phase unwrapping (Karsa and Shmueli 2018), brain masks were



**FIGURE 2** | Axial (A), sagittal (B) and coronal (C) view of the average susceptibility map calculated across MPM acquisitions in a representative sickle cell anemia subject, with the segmented region of interest in the superior sagittal sinus overlaid in red.



**FIGURE 3** | Correlation between QSM and TRUST-based measures of venous oxygen saturation ( $Y_v$ ) in sickle cell anemia (red) and healthy control subjects (blue). Pearson's correlation coefficients ( $r$ ), and the corresponding  $p$  values, are shown for the combined cohort (black), and for the SCA (red) and healthy control (blue) groups. Shaded areas indicate the 95% confidence intervals of the linear regression.

estimated using FSL brain extraction tool (Smith 2002), to account for oblique acquisition images were realigned with the  $B_0$  direction (Kiersnowski et al., 2021) prior to background field removal via projection onto dipole fields (Liu et al., 2011) and susceptibility maps were calculated using the iterative Tikhonov method (Karsa et al., 2020) (Figure 1). To account for head movement between acquisitions, the PD- and MT-weighted images were rigidly transformed into the  $T_1$ -w native space using NiftyReg (Modat et al., 2014). The average  $\chi$  over the three MPM sequences was calculated to reduce noise (Murdoch et al., 2020). The mean  $\chi$  was calculated in a ROI segmented in the SSS using a semi-automated approach in ITK-SNAP (Yushkevich et al., 2006) (Figure 2). This mean  $\chi$  was then used to estimate  $Y_v$  via Eq. 2.

## 2.4 Statistical Analysis

Agreement between QSM and TRUST measures of  $Y_v$  was assessed using correlation and Bland-Altman analyses. Correlations were examined in the SCA and healthy control cohorts, in addition to the combined group. Bland-Altman analysis was carried out separately for the SCA and healthy



controls groups. For each measure of  $Y_v$ , group-wise differences between SCA and HC cohorts were also explored using Student's  $t$ -tests.

## 3 RESULTS

Demographic, laboratory and clinical data are presented in Table 2. Steady state HbF concentrations were available in 13/17 participants with SCA, steady state absolute reticulocyte count (ARC) in 8/17 and lactate dehydrogenase (LDH) levels in 15/17 (Table 2). Compared with our cohort study (Stotesbury et al., 2022), the proportion of patients with SCA and SCI and the rates of hydroxyurea and blood transfusion treatment were similar.

Correlations between the QSM and TRUST-based measures of  $Y_v$  in patients with SCA and healthy controls are shown in Figure 3. In healthy controls, significant correlations were observed between QSM measures of  $Y_v$  and each of the TRUST-based measures, except for measures based on the Bush HbS calibration ( $p = 0.059$ ). In patients with SCA, no such correlations were observed (Figure 1). The strongest





correlations in healthy controls were observed between QSM measures of  $Y_v$  and TRUST measures based on the HbBV ( $R = 0.61$ ,  $p = 0.026$ ) and HbA ( $R = 0.61$ ,  $p = 0.026$ ) calibration models. For the HbS calibration models in healthy controls, weaker correlations with QSM-based estimates of  $Y_v$  were observed. No correlations were observed between QSM- and TRUST-based measures of  $Y_v$ , in either the SCA or the combined group, for any of the TRUST calibration models.

The Bland-Altman analyses (**Figure 4**) showed wide variation in agreement between the QSM and TRUST-based measures of  $Y_v$ , with agreement heavily dependent upon the calibration model used, particularly in patients with SCA. In healthy controls, QSM  $Y_v$  estimates were higher relative to TRUST for most of the calibration models, with mean biases ( $\Delta$ ) of 7.6/10.8/6.5% observed for the HbBV/HbA/HbS<sub>Bush</sub> models respectively. Smaller biases of -1.6% and 0.2% were found for the HbS<sub>Li</sub> and HbS<sub>Li-Bush</sub> models respectively. In the SCA subjects, the direction of the mean bias varied with the calibration model. QSM  $Y_v$  estimates were higher relative to the HbBV and HbA

calibration models ( $\Delta = 9.7\%$  and  $4.7\%$ ) and lower relative to the three HbS models ( $\Delta = -5.8/-8.7/-8.3\%$ ).

The significance and direction of group-wise differences in  $Y_v$  between patients with SCA and healthy controls depended on the  $T_2$  calibration model used (**Figure 5**). Although not statistically significant, both the QSM (64.7% vs. 67.0%,  $p = 0.23$ ) and the HbBV TRUST (55.0% vs. 59.4%,  $p = 0.12$ ) models suggested numerically decreased  $Y_v$  in patients with SCA relative to healthy controls. The HbA model (60.0% vs. 56.2%  $p = 0.09$ ), and the three HbS calibration models (HbS<sub>Bush</sub>/HbS<sub>Li</sub>/HbS<sub>Li-Bush</sub>: 70.5% vs. 60.5%,  $p < 0.001/73.5\%$  vs. 68.6%,  $p = 0.011/73.0\%$  vs. 66.9%,  $p = 0.002$ ) indicated significantly increased  $Y_v$  in patients with SCA relative to healthy controls.

## 4 DISCUSSION

QSM and TRUST based measures of  $Y_v$  were moderately correlated in healthy controls; however poor agreement

between methods was observed in patients with sickle cell anemia. Bland-Altman analyses showed the direction of biases between the QSM and TRUST-based measures of  $Y_v$ , were dependent upon the TRUST calibration model. Group-wise  $Y_v$  differences between SCA patients and healthy controls were further dependent upon the method used to measure  $Y_v$  and were in agreement with previously reported literature.

#### 4.1 Agreement Between QSM and TRUST-Based $Y_v$

This study demonstrates poor agreement between measures of  $Y_v$  in the superior sagittal sinus derived from QSM and TRUST in patients with SCA. In patients with SCA, no significant correlations were observed between the QSM and TRUST measures, for any calibration model relating  $Y_v$  to the measured  $T_2$  of venous blood. If both TRUST and QSM were accurately estimating  $Y_v$ , we would expect strong correlations between the two measures.

The Bland-Altman analysis shows that QSM tended to estimate higher  $Y_v$  in the superior sagittal sinus relative to TRUST in the healthy control subjects for the majority of calibration models. The  $\chi$  of venous blood is determined by the concentration of paramagnetic deoxygenated hemoglobin. Therefore, a higher estimation of  $Y_v$  corresponds to a lower estimation of the  $\chi$  in the superior sagittal sinus. This lower estimation may have been caused by inaccuracies in QSM in the SSS due to its location at the periphery of the brain mask. Any field perturbations outside of the brain, caused by the deoxygenated hemoglobin in the SSS, cannot be sampled, which will reduce the accuracy of  $\chi$  and  $Y_v$  estimates in the vein. One of two published QSM studies of  $Y_v$  in SCA (Shen et al., 2019) considered  $\chi$  values in the straight sinus and reported a mean  $Y_v$  of 69.3% vs. 73.9% in SCA vs. HC compared to 64.7% vs. 67.0% in the SSS in our study. Despite the straight sinus being far away from the edge of the brain mask, the estimates of  $Y_v$  in the straight sinus were even higher than in the SSS in our study. This may have been caused by partial volume effects in this venous structure, which is smaller than the SSS and more challenging to accurately segment, or could have been due to the use of L1 regularization in the  $\chi$  map calculation which is known to underestimate venous  $\chi$  (Berg et al., 2021). The choice of susceptibility calculation method has been shown to have a significant effect on estimates of  $Y_v$ , with Tikhonov-based regularization, as used in this study, shown to be the most accurate method for venous susceptibility measurement in a recent study (Berg et al., 2021).

In the SCA subjects, the direction of the bias between QSM and TRUST methods was dependent upon the calibration model employed. QSM  $Y_v$  measures were increased relative to the HbBV and HbA models and reduced relative to the three HbS models. Examining the Bland-Altman analysis, only the limits of agreement from the QSM-TRUST HbA comparison in healthy controls excluded zero and demonstrated a systematic bias.

#### 4.2 $Y_v$ in SCA vs. Healthy Controls

The results of the group-wise comparisons of  $Y_v$  in patients with SCA versus healthy controls largely agree with the results of previous studies investigating the effect of SCA on  $Y_v$ , and a recent comparison of the models in a pediatric population (Lin et al., 2022). An overview of these previous studies investigating  $Y_v$  in SCA is shown in **Table 1**, with results visualized in **Figure 6**. In the present study, the QSM results suggested numerically decreased  $Y_v$  in SCA relative to healthy controls. These results are in agreement with two prior studies using QSM to estimate  $Y_v$  in SCA (Shen et al., 2019; Murdoch et al., 2021). TRUST with the HbBV calibration model similarly suggested numerically decreased  $Y_v$  in SCA versus healthy controls; in agreement with the prior TRUST study in SCA that employed this model (Jordan et al., 2016). A decrease in  $Y_v$  in patients with SCA relative to healthy controls was also reported in a whole brain study that applied an asymmetric spin-echo based MRI-method and found that whole brain OEF was increased in SCA relative to HC (42.7% vs. 28.8%) (Fields et al., 2018), which is equivalent to a decrease in  $Y_v$  in SCA. However, in the present study, neither the QSM or TRUST HbBV  $Y_v$  differences between patients with SCA and HC reached significance.


Conversely, TRUST with each of the HbS calibration models found  $Y_v$  to be significantly increased in patients with SCA relative to healthy controls. TRUST with the HbA model also suggested elevated  $Y_v$  in SCA but the difference did not reach significance. Our TRUST results using HbS calibration models are in agreement with the results of two TRUST studies in larger cohorts which applied the HbS<sub>Bush</sub> and HbS<sub>Li-Bush</sub> calibration models respectively (Bush et al., 2018; Vu et al., 2021).

Oxygen metabolism in the brain is measured by the cerebral metabolic rate of oxygen (CMRO<sub>2</sub>) which is given by

$$\text{CMRO}_2 = C_a \cdot \text{OEF} \cdot \text{CBF} \quad (3)$$

where  $C_a$  is the arterial oxygen content, the product of  $C_a$  and OEF is the arteriovenous difference in oxygen saturation, and CBF is the cerebral blood flow.

CMRO<sub>2</sub> must be maintained to meet the oxygen demands of the brain, and ischemic stroke occurs when insufficient oxygen is delivered to tissue. In SCA,  $C_a$  is diminished as result of hemolysis and the corresponding reduction in blood hematocrit. It has been shown that CBF increases in SCA to compensate for the reduced arterial content (Bush et al., 2016). It has been hypothesized that OEF might increase in SCA to overcome the reduced  $C_a$  caused by anemia and in some cases oxygen desaturation. The studies reporting a decreased OEF in SCA have attributed this change to arteriovenous shunting (Stotesbury et al., 2019). If OEF is decreased in SCA, corresponding to increased  $Y_v$ , any CBF increase must be sufficiently large to compensate for the decreased  $C_a$  and OEF and ensure sufficient oxygen is supplied to tissue. There is little evidence that CMRO<sub>2</sub> is diminished in SCA as the only published O<sup>15</sup> PET study comparing patients with SCA and healthy controls reported no significant CMRO<sub>2</sub> differences between the two cohorts (Herold et al., 1986).



### 4.3 Validation of QSM and TRUST-Based Measures of $Y_v$

One limitation of our study is the lack of a gold-standard measure of  $Y_v$ , such as  $O^{15}$  PET or jugular vein catheterization, which precluded investigation of the relative accuracy of the QSM and TRUST methods with each of the calibration models, beyond comparison with previously reported values. The Herold et al. PET study found no significant OEF differences between SCA and healthy control groups (SCA: 44% vs. HC: 42%).  $Y_v$  measures from QSM and TRUST with each of the calibration models can be compared with  $O^{15}$  PET estimates of  $Y_v$ : OEF = 44% corresponds to  $Y_v$  = 54% for an assumed arterial oxygen saturation of 98%. In patients with SCA, the TRUST HbBV model provided the closest estimate to the reported PET value (55%) whilst the TRUST method using the Li HbS and Li-Bush HbS calibration models ( $Y_v$  = 73.5% and 73.0% respectively), had the largest difference and may plausibly overestimate  $Y_v$  in SCA (Figure 6). However, it must be noted that the Herold study was conducted in a small population, and additional confounding factors will affect  $Y_v$  measures, including patient treatment.

In SCA patients, neither TRUST nor QSM measures of  $Y_v$  have been validated against gold standard measures. In other populations, QSM-derived OEF has also been compared with gold-standard  $O^{15}$  PET measures of OEF. Kudo et al. compared whole brain OEF measured from QSM using an approach reported by Zaitzu et al. (2011) to the gold-standard  $O^{15}$  PET OEF Kudo et al. (2016). The whole brain OEF maps were estimated from QSM by thresholding the  $\chi$  maps to extract a venous map, and  $Y_v$  was estimated within each vein from the difference between the mean  $\chi$  in each venous voxel relative to the  $\chi$  in the surrounding brain parenchyma. OEF was estimated from

$1 - Y_v$  and a sliding window method was applied within slices to generate venous OEF maps. Significant correlations were observed between QSM and PET OEF measures at a hemispheric level, and QSM-OEF was sensitive to increased hemispherical OEF in patients with chronic unilateral internal carotid or middle cerebral artery stenosis or occlusion.

### 4.4 Limitations of QSM and TRUST Estimation of $Y_v$ in SCA

TRUST can currently only provide an estimate of global  $Y_v$  from just a few voxels whereas QSM can provide  $Y_v$  estimates throughout the venous vasculature. The relatively large dimensions of the TRUST voxels ( $\sim 59 \text{ mm}^3$ ) relative to the QSM voxels ( $1 \text{ mm}^3$ ) limited the number of voxels used to estimate venous  $T_2$  to 4, whilst the mean number of voxels used to estimate the mean  $\chi$  was orders of magnitude greater (mean  $\pm$  standard deviation =  $1225 \pm 793$ ). QSM can be affected by partial volume effects, with the inclusion of non-blood tissue within the ROI likely to result in reduction of the apparent venous  $\chi$  and overestimation of  $Y_v$ . However, the large size of the superior sagittal sinus compared to the QSM voxel size minimizes the risk of partial volume effects (McFadden et al., 2021). In contrast to QSM, the image subtraction performed in TRUST removes signal from static tissue, ensuring that only venous blood contributes to the measured signal.

The TRUST signal model outlined in Eq. 1 shows that the TRUST signal differences are dependent upon both  $T_1$  and  $T_2$  relaxation times. The majority of previous studies have estimated the venous blood  $T_1$  from measured hematocrit levels but  $T_1$  is also dependent on the venous blood oxygenation (Hales et al.,



2016). In our study, venous blood  $T_1$  was estimated using a model developed by Hales et al. (Hales et al., 2016) based on the estimated hematocrit and arterial oxygen saturation measured using pulse oximetry. Pulse oximetry provides an estimate of arterial oxygenation but it is unlikely to accurately represent the venous oxygen saturation, adding another potential confound into TRUST oxygenation measurements.

An alternative method for estimating blood  $T_1$  is to use MRI multi-parametric mapping (MPM), a quantitative imaging method which provides high resolution maps of parameters including  $T_1$  (Lutti et al., 2013). This method is likely more accurate than using the model based on hematocrit and peripheral arterial oxygenation. Here, we used MPM  $T_1$  maps to calculate the mean  $T_1$  within the SSS ROI (used to estimate venous  $\chi$ ), to provide an alternative measure of blood  $T_1$ . Despite differences between the MPM-measured and Hales model-estimated blood  $T_1$  values, these had a negligible effect on the  $T_{2b}$  values estimated by fitting Eq. 1 (Supplementary Materials). This suggests that using estimated blood  $T_1$  values was not a substantial source of error/inaccuracy in the TRUST results in this study.

The study by Li et al. suggested that individual TRUST  $T_2$  calibration models may be required for each SCA patient as blood  $T_2$  is dependent upon factors beyond Hct and  $Y_v$  (Li et al., 2020). Red blood cell shape and the concentration of fetal hemoglobin in the blood were suggested as potential confounds to the  $T_2$  calibration model. Fetal haemoglobin (HbF) differs from adult haemoglobin (HbA) in the globular protein subunits: HbA is comprised of two alpha and two beta subunits, whilst HbF consists of two alpha and two gamma subunits. As the magnetic susceptibility of hemoglobin is determined by oxygenation dependent differences in the electron configuration of the heme iron centres, it is probable that the magnetic susceptibility of deoxygenated HbA and HbF are comparable, but this will require validation.

Hydroxyurea and blood transfusions are known to affect the relative concentrations of HbF and HbA and, given that HbF has a higher oxygen affinity than HbA, these therapies may, therefore, influence venous oxygen saturation. For the 13 patients with sickle cell anemia where steady state fetal hemoglobin levels were available, only 1 patient receiving hydroxyurea had unusually elevated HbF levels (>20%). Therefore, elevated HbF levels in the SCA cohort are unlikely to have had a confounding effect on the groupwise comparison results shown in Figure 5.

Future validation of QSM measures of  $Y_v$  in patients with SCA would be strengthened by measuring the hemoglobin composition to investigate any potential confounding effects of the proportion of HbF/HbA/HbS.

Blood rheology has been shown to be modified in patients with sickle cell anemia (Connes et al., 2016). QSM and TRUST models are dependent upon blood hematocrit levels, a key determinant of blood viscosity. However, the possible effects of blood rheology on venous  $T_2$ , flow and oxygenation in SCA or the potential effects of increased fibrinogen levels on blood susceptibility have not been investigated and could be explored in future work.

Accurate MRI measures of venous oxygen saturation in patients with sickle cell anemia would provide a useful biomarker when evaluating the efficacy of novel treatments. Of particular interest would be hemoglobin oxygen modifying therapies, for example Voxelotor (Oxbryta), which aims to reduce sickling by stabilizing HbS in an oxygenated state (Herity et al., 2021). It would be expected that prevention of HbS sickling would increase arterial oxygen capacity and, therefore, venous oxygen saturation, which could be quantified using the MRI measures compared in this study.

This study is limited by the relatively low numbers of patients with SCA and healthy controls, as well as by the use of estimated hematocrit values for 5/17 SCA subjects and all the healthy control subjects. QSM measures of  $Y_v$  were restricted to the SSS for the purpose of comparison with the TRUST results, which are limited to the SSS due to the low resolution, coverage and SNR of the TRUST MRI acquisition. QSM can provide local measures of  $Y_v$  in any venous structures which can be segmented (McFadden et al., 2021). We would expect localized changes in  $Y_v$  in SCA, as evidenced by the high incidence of ischemic stroke in the internal carotid and middle cerebral artery territories (Adams 1995; Pavlakis and Levinson 2009). Any localized changes in  $Y_v$  in SCA may only have a small effect in the SSS as many veins drain into the SSS, and future work should consider applying QSM to measure  $Y_v$  beyond the major draining veins.

## 5 CONCLUSION

This study compares QSM and TRUST measures of venous oxygenation ( $Y_v$ ) in patients with sickle cell anemia. QSM and TRUST-based  $Y_v$  in the superior sagittal sinus were significantly correlated in healthy controls using all but one TRUST calibration model (HbS<sub>Bush</sub>). However, in patients with sickle cell anemia, we observed disagreement between QSM and TRUST measures of venous oxygen saturation in the superior sagittal sinus. QSM measures of  $Y_v$  suggested decreased  $Y_v$  in SCA relative to healthy controls in agreement with TRUST measures of  $Y_v$  using a bovine hemoglobin calibration model and previous studies using asymmetric spin-echo methods. This is opposite to the increased  $Y_v$  in SCA relative to healthy controls found here and in previous studies using TRUST methods based on sickle hemoglobin calibration models. Further validation of all MRI measures of  $Y_v$ , relative to ground truth measures such as  $O^{15}$  PET and jugular vein catheterization, is required in SCA before QSM or TRUST methods can be considered for neurological risk prediction in clinical practice.

## DATA AVAILABILITY STATEMENT

Full anonymized data will be shared on request from qualified investigators.

## ETHICS STATEMENT

The studies involving human participants were reviewed and approved by the West London NHS (05/Q0408/42, 11/EM/0084, 15/LO/0347) Yorkshire NHS (15/YH/0213) University College London (14475/001). Written informed consent to participate in this study was provided by the participants' legal guardian/next of kin.

## AUTHOR CONTRIBUTIONS

RM: manuscript preparation, QSM data processing. HS: manuscript preparation, data acquisition, TRUST data processing. PH: TRUST data processing. JK: data acquisition. MK: data acquisition. CC: manuscript review, oversaw set-up of imaging protocol. FK: manuscript review, data acquisition. KS: manuscript review, QSM data processing.

## FUNDING

HS and MK were funded by Action Medical Research (GN2509) and JK by Great Ormond Street Children's Charity (V4615). The work was supported by the National Institute for Health Research

## REFERENCES

- Adams, R. J. (1995). Sickle Cell Disease and Stroke. *J. Child. Neurol.* 10 (2), 75–76. doi:10.1177/088307389501000201
- Berg, R. C., Preibisch, C., Thomas, D. L., Shmueli, K., and Biondetti, E. (2021). Investigating the Effect of Flow Compensation and Quantitative Susceptibility Mapping Method on the Accuracy of Venous Susceptibility Measurement. *NeuroImage* 240, 118399. doi:10.1016/j.neuroimage.2021.118399
- Biondetti, E., Rojas-Villabona, A., Sokolska, M., Pizzini, F. B., Jäger, H. R., Thomas, D. L., et al. (2019). Investigating the Oxygenation of Brain Arteriovenous Malformations Using Quantitative Susceptibility Mapping. *Neuroimage* 199, 440–453. doi:10.1016/j.neuroimage.2019.05.014
- Bush, A., Borzage, M., Detterich, J., Kato, R. M., Meiselman, H. J., Coates, T., et al. (2017). Empirical Model of Human Blood Transverse Relaxation at 3 T Improves MRI T2oximetry. *Magn. Reson. Med.* 77 (6), 2364–2371. doi:10.1002/mrm.26311
- Bush, A. M., Borzage, M. T., Choi, S., Václavů, L., Tamrazi, B., Nederveen, A. J., et al. (2016). Determinants of Resting Cerebral Blood Flow in Sickle Cell Disease. *Am. J. Hematol.* 91 (9), 912–917. doi:10.1002/ajh.24441
- Bush, A. M., Coates, T. D., and Wood, J. C. (2018). Diminished Cerebral Oxygen Extraction and Metabolic Rate in Sickle Cell Disease Using T2 Relaxation under Spin Tagging MRI. *Magn. Reson. Med.* 80 (1), 294–303. doi:10.1002/mrm.27015
- Bush, A., Vu, C., Choi, S., Borzage, M., Miao, X., Li, W., et al. (2021). Calibration of T2 Oximetry MRI for Subjects with Sickle Cell Disease. *Magn. Reson. Med.* 86 (2), 1019–1028. doi:10.1002/mrm.28757
- Castro, O. L., Haddy, T. B., and Rana, S. R. (1987). Age- and Sex-Related Blood Cell Values in Healthy Black Americans. *Public Health Rep.* 102 (2), 232–237.
- Connes, P., Alexy, T., Detterich, J., Romana, M., Hardy-Dessources, M.-D., Ballas, S. K., et al. (2016). The Role of Blood Rheology in Sickle Cell Disease. *Blood Rev.* 30 (2), 111–118. doi:10.1016/j.blre.2015.08.005
- Debaun, M. R., and Kirkham, F. J. (2016). Central Nervous System Complications and Management in Sickle Cell Disease. *Blood* 127 (7), 829–838. doi:10.1182/blood-2015-09-618579
- Eldeniz, C., Binkley, M. M., Fields, M., Williams, K., Ragan, D. K., Chen, Y., et al. (2021). Bulk Volume Susceptibility Difference between Deoxyhemoglobin and

Biomedical Research Centre (IS-BRC-1215–20012) at Great Ormond Street Hospital for Children NHS Foundation Trust and University College London. The work was supported by a UCL Grand Challenges Doctoral Students Grant. KS is funded by European Research Council Consolidator Grant DiSCo MRI SFN 770939. RM was supported by the EPSRC-funded UCL Centre for Doctoral Training in Medical Imaging (EP/L016478/1) and the Department of Health's NIHR-funded Biomedical Research Centre at Great Ormond Street Hospital (IS-BRC-1215–20012).

## ACKNOWLEDGMENTS

The authors would like to thank the patients and controls who participated in this research and their families. They would also like to thank the Great Ormond Street Hospital research radiographers for their efforts: Tina Banks, Jessica Cooper, Nichola Sellers, Paul Xavier, Bella Said, Jorvaar Gill, and Michelle Quigley.

## SUPPLEMENTARY MATERIAL

The Supplementary Material for this article can be found online at: <https://www.frontiersin.org/articles/10.3389/fphys.2022.913443/full#supplementary-material>

- Oxyhemoglobin for HbA and HbS: A Comparative Study. *Magn. Reson. Med.* 85 (6), 3383–3393. doi:10.1002/mrm.28668
- Fan, A. P., KhalilKhalil, A. A., Fiebach, J. B., Zaharchuk, G., Fiebach, J. B., Zaharchuk, G., et al. (2020). Elevated Brain Oxygen Extraction Fraction Measured by MRI Susceptibility Relates to Perfusion Status in Acute Ischemic Stroke. *J. Cereb. Blood Flow Metab.* 40 (3), 539–551. doi:10.1177/0271678x19827944
- Fields, M. E., Williams, K. P., Ragan, D. K., Binkley, M. M., Eldeniz, C., Chen, Y., et al. (2018). Regional Oxygen Extraction Predicts Border Zone Vulnerability to Stroke in Sickle Cell Disease. *Neurology* 90 (13), e1134–e1142. doi:10.1212/wnl.0000000000005194
- Hales, P. W., Kirkham, F. J., and Clark, C. A. (2016). A General Model to Calculate the Spin-Lattice (T1) Relaxation Time of Blood, Accounting for Haematocrit, Oxygen Saturation and Magnetic Field Strength. *J. Cereb. Blood Flow. Metab.* 36 (2), 370–374. doi:10.1177/0271678x15605856
- Herity, L. B., Vaughan, D. M., Rodriguez, L. R., and Lowe, D. K. (2021). Dale Marie M. Vaughan, Lindsey Ritenour Rodriguez, and Denise Kozella LoweVoxelot: A Novel Treatment for Sickle Cell Disease. *Ann. Pharmacother.* 55 (2), 240–245. doi:10.1177/1060028020943059
- Herold, S., Brozovic, M., Gibbs, J., Lammertsma, A. A., Leenders, K. L., Carr, D., et al. (1986). Measurement of Regional Cerebral Blood Flow, Blood Volume and Oxygen Metabolism in Patients with Sickle Cell Disease Using Positron Emission Tomography. *Stroke* 17 (4), 692–698. doi:10.1161/01.str.17.4.692
- Howard, J., April, E. S., Skene, S., Inusa, B., Kawadler, J., Downes, M., et al. (2018). Overnight Auto-Adjusting Continuous Airway Pressure+standard Care Compared with Standard Care Alone in the Prevention of Morbidity in Sickle Cell Disease Phase II (POMS2b): Study Protocol for a Randomised Controlled Trial. *Trials* 19 (1), 1–10. doi:10.1186/s13063-017-2419-0
- Jain, V., Abdulmalik, O., Propert, K. J., and Wehrli, F. W. (2012). Investigating the Magnetic Susceptibility Properties of Fresh Human Blood for Noninvasive Oxygen Saturation Quantification. *Magn. Reson. Med.* 68 (3), 863–867. doi:10.1002/mrm.23282
- Jordan, L. C., Gindville, M. C., Scott, A. O., Juttukonda, M. R., Strother, M. K., Kassim, A. A., et al. (2016). “Non-Invasive Imaging of Oxygen Extraction Fraction in Adults with Sickle Cell Anaemia.” *Brain* 139 (3), 738–750. doi:10.1093/brain/aww397
- Jordan, L. C., and DeBaun, M. R. (2018). Cerebral Hemodynamic Assessment and Neuroimaging across the Lifespan in Sickle Cell Disease. *J. Cereb. Blood Flow. Metab.* 38 (9), 1438–1448. doi:10.1177/0271678x17701763

- Karsa, A., and Shmueli, K. (2018). SEGUE: A Speedy Region-Growing Algorithm for Unwrapping Estimated Phase. *IEEE Trans. Med. Imaging* 38 (6), 1347–1357. doi:10.1109/TMI.2018.2884093
- Karsa, A., Punwani, S., and Shmueli, K. (2020). An Optimized and Highly Repeatable MRI Acquisition and Processing Pipeline for Quantitative Susceptibility Mapping in the Head-And-Neck Region. *Magn. Reson. Med.* 84, 3206–3222. doi:10.1002/mrm.28377
- Kiersnowski, Oliver C., Karsa, A., Wastling, S. J., Thornton, J. S., and Shmueli, K. (2021). The Effect of Oblique Image Acquisition on the Accuracy of Quantitative Susceptibility Mapping and a Robust Tilt Correction Method. *bioRxiv*.
- Kratz, A., Ferraro, M., Sluss, P. M., and Lewandrowski, K. B. (2004). Laboratory Reference Values. *New England J. Med.* 351, 1548–1564.
- Kudo, K., Liu, T., Murakami, T., Goodwin, J., Uwano, I., Yamashita, F., et al. (2016). Oxygen Extraction Fraction Measurement Using Quantitative Susceptibility Mapping: Comparison with Positron Emission Tomography. *J. Cereb. Blood Flow. Metab.* 36 (8), 1424–1433. doi:10.1177/0271678x15606713
- Li, W., Xu, X., Liu, P., Strouse, J. J., Casella, J. F., Lu, H., et al. (2020). Quantification of Whole-Brain Oxygenation Extraction Fraction and Cerebral Metabolic Rate of Oxygen Consumption in Adults with Sickle Cell Anemia Using Individual T<sub>2</sub>-based Oxygenation Calibrations. *Magn. Reson. Med.* 83 (3), 1066–1080. doi:10.1002/mrm.27972
- Lin, Z., McIntyre, T., Jiang, D., Cannon, A., Liu, P., Tekes, A., et al. (2022). Brain Oxygen Extraction and Metabolism in Pediatric Patients with Sickle Cell Disease: Comparison of Four Calibration Models. *Front. Physiology* 13 (February), 1–11. doi:10.3389/fphys.2022.814979
- Liu, T., Khalidov, I., de Rochefort, L., Spincemaille, P., Liu, J., Tsiouris, A. J., et al. (2011). A Novel Background Field Removal Method for MRI Using Projection onto Dipole Fields (PDF). *NMR Biomed.* 24 (9), 1129–1136. doi:10.1002/nbm.1670
- Liu, T., Wisnieff, C., Lou, M., Chen, W., Spincemaille, P., and Wang, Y. (2013). Nonlinear Formulation of the Magnetic Field to Source Relationship for Robust Quantitative Susceptibility Mapping. *Magn. Reson. Med.* 69 (2), 467–476. doi:10.1002/mrm.24272
- Lu, H., Xu, F., Grgac, K., Liu, P., Qin, Q., and Van Zijl, P. (2012). Calibration and Validation of TRUST MRI for the Estimation of Cerebral Blood Oxygenation. *Magn. Reson. Med.* 67 (1), 42–49. doi:10.1002/mrm.22970
- McFadden, J. J., Matthews, J. C., Lauren, A. S., Parker, G. J. M., Lohéziec, M., and Parkes, L. M. (2021). Optimization of Quantitative Susceptibility Mapping for Regional Estimation of Oxygen Extraction Fraction in the Brain. *Magnetic Reson. Med.*, 86(3) 1–16. doi:10.1002/mrm.28789
- Modat, M., Cash, D. M., Daga, P., Winston, G. P., Duncan, J. S., and Ourselin, S. (2014). Global Image Registration Using a Symmetric Block-Matching Approach. *J. Med. Imag.* 1 (2), 024003. doi:10.1117/1.jmi.1.2.024003
- Murdoch, R., Kawadler, J., Carmichael, D., Kirkham, F., and Shmueli, K. (2020). “Can Multi-Parametric Mapping Sequences Be Used for Accurate Quantitative Susceptibility Mapping?” in Proceedings of the 2020 ISMRM and SMRT Virtual Conference and Exhibition. (International Society for Magnetic Resonance in Medicine (ISMRM)).
- Murdoch, R., Stotesbury, H., Kawadler, J., Saunders, D., Kirkham, F., and Shmueli, K. (2021). “Investigating the Effect of Positive Airways Pressure on Venous Oxygenation in Sickle Cell Anemia with Quantitative Susceptibility Mapping.” in Proceedings of the 2021 ISMRM and SMRT Annual Meeting and Exhibition. (International Society for Magnetic Resonance in Medicine (ISMRM)).
- Pavlikis, S. G., and Levinson, K. (2009). Arterial Ischemic Stroke: Common Risk Factors in Newborns and Children. *Stroke* 40 (3 Suppl.), S79–S81. doi:10.1161/STROKEAHA.108.531749
- Rosen, C. L., Debaun, M. R., Strunk, R. C., Redline, S., Seicean, S., Craven, D. I., et al. (2014). Obstructive Sleep Apnea and Sickle Cell Anemia. *Pediatrics* 134 (2), 273–281. doi:10.1542/peds.2013-4223
- Shen, J., Coates, T., and Wood, J. C. (2019). Lower Oxygen Saturation in the Internal Cerebral Vein of Patients with Sickle Cell Disease Revealed by Qsm-MRI. *Blood* 134, 984. doi:10.1182/blood-2019-131968
- Shmueli, K. (2020). “Quantitative Susceptibility Mapping,” in *Quantitative Magnetic Resonance Imaging* (Academic Press), Cambridge, Massachusetts, United States, 1, 819–838. doi:10.1016/b978-0-12-817057-1.00033-0
- Smith, S. M. (2002). Fast Robust Automated Brain Extraction. *Hum. Brain Mapp.* 17 (3), 143–155. doi:10.1002/hbm.10062
- Stotesbury, H., Kawadler, J. M., Hales, P. W., Saunders, D. E., Clark, C. A., and Kirkham, F. J. (2019). Vascular Instability and Neurological Morbidity in Sickle Cell Disease: An Integrative Framework. *Front. Neurol.* 10 (AUG), 21. doi:10.3389/fneur.2019.00871
- Stotesbury, H., Hales, P. W., Koelbel, M., Hood, A. M., Kawadler, J. M., Saunders, D. E., et al. (2022). Venous Cerebral Blood Flow Quantification and Cognition in Patients with Sickle Cell Anemia. *J. Cereb. Blood Flow. Metabolism.* 42(6): 1061–1077. doi:10.1177/0271678x211072391
- Stotesbury, H., Hales, P. W., and Kirkham, F. J. (2018). The Promise of Noninvasive Cerebral Hemodynamic Assessment in Sickle Cell Anemia. *Neurology* 90 (13), 585–586. doi:10.1212/wnl.0000000000005236
- Stotesbury, H., Kawadler, J. M., Saunders, D. E., and Kirkham, F. J. (2021). MRI Detection of Brain Abnormality in Sickle Cell Disease. *Expert Rev. Hematol.* 14 (5), 473–491. doi:10.1080/17474086.2021.1893687
- Vu, C., Bush, A., Choi, S., Borzage, M., Miao, X., Nederveen, A. J., et al. (2021). Reduced Global Cerebral Oxygen Metabolic Rate in Sickle Cell Disease and Chronic Anemias. *Am. J. Hematol.* 96 (8), 901–913. doi:10.1002/ajh.26203
- Weiskopf, N., Suckling, J., Williams, G., Correia, M. M., Inkster, B., Tait, R., et al. (2013). Quantitative Multi-Parameter Mapping of R1, PD(\*), MT, and R2(\*) at 3T: A Multi-Center Validation. *Front. Neurosci.* 7 (7 JUN), 95. doi:10.3389/fnins.2013.00095
- Weisskoff, R. M., and Kiihne, S. (1992). MRI Susceptometry: Image-Based Measurement of Absolute Susceptibility of MR Contrast Agents and Human Blood. *Magn. Reson. Med.* 24 (24), 375–383. doi:10.1002/mrm.1910240219
- Yushkevich, P. A., Piven, J., Hazlett, H. C., Smith, R. G., Ho, S., Gee, J. C., et al. (2006). User-Guided 3D Active Contour Segmentation of Anatomical Structures: Significantly Improved Efficiency and Reliability. *NeuroImage* 31 (3), 1116–1128. doi:10.1016/j.neuroimage.2006.01.015
- Zaitsu, Y., Kudo, K., Terae, S., Yazu, R., Ishizaka, K., Fujima, N., et al. (2011). Mapping of Cerebral Oxygen Extraction Fraction Changes with Susceptibility-Weighted Phase Imaging. *Radiology* 261 (3), 930–936. doi:10.1148/radiol.11102416

**Conflict of Interest:** The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

**Publisher’s Note:** All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Copyright © 2022 Murdoch, Stotesbury, Hales, Kawadler, Kölbl, Clark, Kirkham and Shmueli. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.